Deal overview

Deal overview
Target CATALENT INC
Bidder NOVO HOLDINGS A/S
Price £90.00 Full version or £25.00 Light version
Publication Date Feb 05, 2024
Abstract On 5 February 2024, the Danish life sciences investor Novo Holdings A/S ("Novo") announced a recommended cash offer for 100% of the quoted US pharmaceuticals manufacturer Catalent Inc ("Catalent"). Novo would pay US$ 63.5 per Catalent share, which implied an equity value of US$ 11.7 billion for 100% of Catalent's share capital. Elliott Investment Management LP and certain ...
Number of pages (Full version) 9
Number of pages (Light version) 2
Format Adobe Acrobat (Download Acrobat Reader)
Free Sample Click Here to Download

Purchase this report

Accepted credit cards: Visa, America Express, Master Card

Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.

Back to search results

Page Time: 0.015423s